Acceleron Pharma Inc. XLRN
178.75 +178.75
Day range unavailable
52-week range unavailable
- Forward P/E
- -54.17
- Analysts
- Buy
- Price target
- 178.88 (+0.1%)
- Earnings date
- Nov 4, 2021
YTD +5.04 (+2.90%)
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 169.49
- 200-day average
- 137.95
Analyst view
Consensus: buy
Buy
Price target (mean) 178.88 +0.1% upside
Now 178.75
- Target (low)
- 171.00
- Target (mean)
- 178.88
- Target (high)
- 180.00
Ratings (0m) 15 11 buy · 3 hold · 1 sell
- Strong buy3
- Buy8
- Hold3
- Sell1
- Strong sell0
Next earnings
Nov 4, 2021
Expected Nov 4, 2021. Consensus EPS estimate -0.93.
Financials — quick view
XLRN Revenue — quarterly 34.20M
XLRN Net income — quarterly -70.47M
XLRN EPS — quarterly -1.16
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2021 | Sep 1, 2021 | -0.96 | — | — | — |
| Aug 5, 2021 | Jun 1, 2021 | -0.92 | — | — | — |
| May 6, 2021 | Mar 1, 2021 | -0.83 | — | — | — |
| Feb 25, 2021 | Dec 1, 2020 | -0.66 | — | — | — |
| Nov 5, 2020 | Sep 1, 2020 | -0.55 | — | — | — |
| Aug 6, 2020 | Jun 1, 2020 | -0.55 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2021 | Jefferies | init | — | Hold |
| Oct 4, 2021 | Raymond James | down | Strong Buy | Market Perform |
| Oct 1, 2021 | Morgan Stanley | down | Overweight | Equal-Weight |
| Oct 1, 2021 | Barclays | down | Overweight | Equal-Weight |
| Oct 1, 2021 | Cowen & Co. | down | Outperform | Market Perform |
| Sep 30, 2021 | HC Wainwright & Co. | down | Buy | Neutral |
News
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data 
Earnings Scheduled For August 5, 2021 
Earnings Scheduled For May 6, 2021 
52 Weeks High Article 0.7186450125908432 - Stocks Making New 52-Week Highs/Lows For Monday, Feb. 22, 2021 (Via Benzinga Pro's Signals Tool)
Stocks That Hit 52-Week Highs On Monday - Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Highs On Monday - Stocks That Hit 52-Week Highs On Wednesday
- Stocks That Hit 52-Week Highs On Tuesday
Your note
Sign in to keep a note on XLRN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DABLE HABIB J. | Chief Executive Officer | Sale | Jul 1, 2021 | 98,450 |
| HAMILL LAURA | Director | Stock Award(Grant) | Jan 28, 2021 | 474 |
| KANGO SUJAY R | Officer | Sale | Mar 1, 2021 | 19,396 |
| KEARNEY TERRENCE C | Director | Stock Award(Grant) | Jan 28, 2021 | 6,749 |
| MCCOURT THOMAS A | Director | Sale | Apr 18, 2021 | 6,044 |
| MCLAUGHLIN KEVIN F | Chief Financial Officer | Stock Award(Grant) | Jan 28, 2021 | 10,681 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Associates Inc | 8.77% | 5,365,133 | 923.34M | Sep 29, 2021 |
| Vanguard Group, Inc. (The) | 8.05% | 4,925,189 | 847.63M | Sep 29, 2021 |
| Avoro Capital Advisors LLC | 6.54% | 4,000,000 | 688.40M | Sep 29, 2021 |
| Blackrock Inc. | 6.50% | 3,972,924 | 683.74M | Sep 29, 2021 |
| Farallon Capital Management Llc | 3.54% | 2,164,663 | 372.54M | Sep 29, 2021 |
| FMR, LLC | 3.39% | 2,072,735 | 356.72M | Sep 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.52% | 1,543,858 | 193.74M | Jun 29, 2021 |
| Price (T.Rowe) New Horizons Fund | 2.34% | 1,432,837 | 179.81M | Jun 29, 2021 |
| Price (T.Rowe) Health Sciences Fund | 2.33% | 1,427,089 | 179.09M | Jun 29, 2021 |
| Vanguard Small-Cap Index Fund | 2.22% | 1,359,230 | 170.57M | Jun 29, 2021 |
| Vanguard Small-Cap Growth Index Fund | 1.40% | 858,419 | 107.72M | Jun 29, 2021 |
| Fidelity Select Portfolios - Biotechnology | 1.38% | 842,586 | 145.01M | Sep 29, 2021 |